-
Amsterdam UMC leads global research to stop Crohn's disease
Crohn's disease is advancing rapidly in the Western world. The international consortium INTERCEPT, led by Amsterdam UMC, will investigate how this disease can be detected and stopped at an early stage. "If this succeeds, the health benefits for society will be enormous," says Geert D'Haens, professor of Inflammatory Bowel Diseases and head of the department of gastroenterology and liver disease at Amsterdam UMC. To carry out this investigation, the consortium will receive a European grant of 37.5 million euros.
-
Burning away liver metastases in patients with colorectal cancer offers faster recovery and fewer complications
Heating (thermal ablation) of small metastases in the liver in patients with colon cancer results in fewer complications and allows the patient to return home faster, all while providing a similar chance of survival as surgically removing the tumours. These are the headline results of the COLLISION trail, carried out by Amsterdam UMC and the Dutch Colorectal Cancer Group, published today in The Lancet Oncology.
-
New Parkinson's treatment method in which the brain itself controls implanted electrodes
In deep brain stimulation (DBS), implanted electrodes continuously deliver shocks, pulses, to the brains of patients with Parkinson's disease or neurological or psychiatric disorders. Usually the symptoms, such as trembling, are reduced as a result. Sometimes, however, the effect is limited, or the treatment causes side effects. Adaptive DBS (aDBS) can offer a solution by only giving pulses when the patient's brain itself asks for them. Amsterdam UMC neurologist Martijn Beudel has been researching aDBS for over 10 years. On 13 January, the first patient in the world was treated 'tailor-made' with this method outside of study.
-
Working together against rare diseases
To ensure that patients with rare diseases can count on the right care everywhere in Europe, the European Commission created the Reference Networks in 2017. These ERNs are now also increasingly active in research and education and have achieved a central position in the academic world. Also at Amsterdam UMC, where 2 of the 24 networks are coordinated.
-
Genomic Study Reveals Causal Link Between PTSD and Cardiovascular Disease, Offering New Insights for Prevention and Treatment
Those with posttraumatic stress disorder (PTSD) are at increased risk of cardiovascular diseases. Why this is, remains unknown. Researchers from Amsterdam UMC and Yale University analysed the genomic data of more than a million individuals and found a shared genetic predisposition for both PTSD and cardiovascular disease. Further, they found strong evidence that PTSD causally increases the risk of cardiovascular diseases. This study is published today in Translational Psychiatry.
-
Cookie statement
-
Amsterdam UMC
-
Disclaimers
-
Hormone therapy reshapes the skeleton in transgender individuals who previously blocked puberty
Skeletal size may be altered by gender-affirming hormone therapy only if puberty has also been suppressed during adolescence, according to research presented at the 62nd Annual European Society for Paediatric Endocrinology Meeting in Liverpool. The findings from this research, carried out by Amsterdam UMC, not only help researchers further understand the roles sex hormones play on the skeleton but may also improve counselling on gender-affirming treatment in transgender individuals.
-
PhD graduation
Timeline and information of your PhD graduation at Amsterdam UMC.
-
Study quantifies impact of rapid first shock after cardiac arrest
It is well known that acting quickly in the event of a cardiac arrest is important, but what does a quick initial shock with a defibrillator mean exactly for patients' chances of survival? Researchers from Amsterdam UMC analysed the data of 3723 patients who had a cardiac arrest outside the hospital and concluded that for the first shock, every minute reduces the chance of survival by 6%. The results of this research were published in the journal Circulation.
-
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death. Confirming the findings published earlier this year from researchers from Amsterdam UMC, the University of Auckland and Cambridge University Hospitals NHS Foundation Trust. This phase two study is published today in the New England Journal of Medicine and presented at American College of Allergy, Asthma & Immunology's annual congress on the 26th of October.
